Menu Search
Equities

SSY Group Ltd

LJUIF:PKC

SSY Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.6987
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 01 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.

  • Revenue in HKD (TTM)6.47bn
  • Net income in HKD1.37bn
  • Incorporated2004
  • Employees5.80k
  • Location
    SSY Group LtdRooms 4902-03, 49th Floor, Central Plaza18 Harbour RoadWanchai Hong KongHKG
  • Phone+852 26880869
  • Fax+852 27873338
  • Websitehttp://www.ssygroup.com.hk/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.